Deciphering the chronology of copy number alterations in Multiple Myeloma

[1]  D. Dingli,et al.  Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi‐parametric flow cytometry method , 2019, American journal of hematology.

[2]  O. Stephens,et al.  Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing , 2017, Nature Communications.

[3]  Nicholas Navin,et al.  Tumor evolution: Linear, branching, neutral or punctuated? , 2017, Biochimica et biophysica acta. Reviews on cancer.

[4]  N. Munshi,et al.  Genomics of Multiple Myeloma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Landau,et al.  Genomic complexity of multiple myeloma and its clinical implications , 2017, Nature Reviews Clinical Oncology.

[6]  M. Moarii,et al.  Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. , 2017, Leukemia.

[7]  G. Morgan,et al.  Genomewide profiling of copy‐number alteration in monoclonal gammopathy of undetermined significance , 2016, European journal of haematology.

[8]  T. Golub,et al.  Genetic interrogation of circulating multiple myeloma cells at single-cell resolution , 2016, Science Translational Medicine.

[9]  M. Mohty,et al.  Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? , 2015, Blood.

[10]  S. Rajkumar,et al.  Smoldering multiple myeloma. , 2015, Blood.

[11]  N. Munshi,et al.  Genetics of multiple myeloma: another heterogeneity level? , 2015, Blood.

[12]  T. Chevassut,et al.  The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.

[13]  G. Parmigiani,et al.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.

[14]  Parantu K. Shah,et al.  The shaping and functional consequences of the dosage effect landscape in multiple myeloma , 2013, BMC Genomics.

[15]  Parantu K. Shah,et al.  Classify Hyperdiploidy Status of Multiple Myeloma Patients Using Gene Expression Profiles , 2013, PloS one.

[16]  G. Morgan,et al.  The genetic architecture of multiple myeloma , 2012, Nature Reviews Cancer.

[17]  D. Hose,et al.  Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). , 2011, Blood.

[18]  N. Munshi,et al.  Genomics of Multiple Myeloma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Gutiérrez,et al.  The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells , 2010, Clinical Cancer Research.

[20]  R. Kyle,et al.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. , 2010, Mayo Clinic proceedings.

[21]  Mehmet Koyutürk,et al.  An optimization framework for unsupervised identification of rare copy number variation from SNP array data , 2009, Genome Biology.

[22]  Cheng Li,et al.  Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Therneau,et al.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.

[24]  Rafael Fonseca,et al.  Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. , 2007, Cancer research.

[25]  G. Ahmann,et al.  Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations , 2006, Leukemia.

[26]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[27]  G. Ahmann,et al.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. , 2005, Blood.

[28]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.

[30]  R. Kominami.  A sensitive assay for detecting mutations resulting from unequal homologous recombination without phenotypic selection. , 1990, Mutation research.